Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines

Mycobacterium tuberculosis (M. tuberculosis) is an intracellular pathogen causing long-term infection in humans that mainly attacks macrophages and can escape from the immune system with the various mechanisms. The only FDA-approved vaccine against M. tuberculosis (MTB) is Mycobacterium bovis bacill...

Descripción completa

Detalles Bibliográficos
Autores principales: Valizadeh, Azar, imani Fooladi, Abbas Ali, Sedighian, Hamid, Mahboobi, Mahdieh, Gholami Parizad, Elaheh, Behzadi, Elham, Khosravi, Afra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295111/
https://www.ncbi.nlm.nih.gov/pubmed/35852636
http://dx.doi.org/10.1007/s00284-022-02949-8
_version_ 1784749991523254272
author Valizadeh, Azar
imani Fooladi, Abbas Ali
Sedighian, Hamid
Mahboobi, Mahdieh
Gholami Parizad, Elaheh
Behzadi, Elham
Khosravi, Afra
author_facet Valizadeh, Azar
imani Fooladi, Abbas Ali
Sedighian, Hamid
Mahboobi, Mahdieh
Gholami Parizad, Elaheh
Behzadi, Elham
Khosravi, Afra
author_sort Valizadeh, Azar
collection PubMed
description Mycobacterium tuberculosis (M. tuberculosis) is an intracellular pathogen causing long-term infection in humans that mainly attacks macrophages and can escape from the immune system with the various mechanisms. The only FDA-approved vaccine against M. tuberculosis (MTB) is Mycobacterium bovis bacillus Calmette-Guérin (BCG). The protection of this vaccine typically lasts 10–15 years. Due to the increasing number of people becoming ill with MTB each year worldwide, the need to develop a new effective treatment against the disease has been increased. During the past two decades, the research budget for TB vaccine has quadrupled to over half a billion dollars. Most of these research projects were based on amplifying and stimulating the response of T-cells and developing the subunit vaccines. Additionally, these studies have demonstrated that secretory and immunogenic proteins of MTB play a key role in the pathogenesis of the bacteria. Therefore, these proteins were used to develop the new subunit vaccines. In this review, based on the use of these proteins in the successful new subunit vaccines, the PPE44, HSPX, CFP-10 and ESAT-6 antigens were selected and the role of these antigens in designing and developing new subunit vaccines against TB and for the prevention of TB were investigated.
format Online
Article
Text
id pubmed-9295111
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-92951112022-07-19 Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines Valizadeh, Azar imani Fooladi, Abbas Ali Sedighian, Hamid Mahboobi, Mahdieh Gholami Parizad, Elaheh Behzadi, Elham Khosravi, Afra Curr Microbiol Review Article Mycobacterium tuberculosis (M. tuberculosis) is an intracellular pathogen causing long-term infection in humans that mainly attacks macrophages and can escape from the immune system with the various mechanisms. The only FDA-approved vaccine against M. tuberculosis (MTB) is Mycobacterium bovis bacillus Calmette-Guérin (BCG). The protection of this vaccine typically lasts 10–15 years. Due to the increasing number of people becoming ill with MTB each year worldwide, the need to develop a new effective treatment against the disease has been increased. During the past two decades, the research budget for TB vaccine has quadrupled to over half a billion dollars. Most of these research projects were based on amplifying and stimulating the response of T-cells and developing the subunit vaccines. Additionally, these studies have demonstrated that secretory and immunogenic proteins of MTB play a key role in the pathogenesis of the bacteria. Therefore, these proteins were used to develop the new subunit vaccines. In this review, based on the use of these proteins in the successful new subunit vaccines, the PPE44, HSPX, CFP-10 and ESAT-6 antigens were selected and the role of these antigens in designing and developing new subunit vaccines against TB and for the prevention of TB were investigated. Springer US 2022-07-19 2022 /pmc/articles/PMC9295111/ /pubmed/35852636 http://dx.doi.org/10.1007/s00284-022-02949-8 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Valizadeh, Azar
imani Fooladi, Abbas Ali
Sedighian, Hamid
Mahboobi, Mahdieh
Gholami Parizad, Elaheh
Behzadi, Elham
Khosravi, Afra
Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines
title Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines
title_full Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines
title_fullStr Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines
title_full_unstemmed Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines
title_short Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines
title_sort evaluating the performance of ppe44, hspx, esat-6 and cfp-10 factors in tuberculosis subunit vaccines
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295111/
https://www.ncbi.nlm.nih.gov/pubmed/35852636
http://dx.doi.org/10.1007/s00284-022-02949-8
work_keys_str_mv AT valizadehazar evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines
AT imanifooladiabbasali evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines
AT sedighianhamid evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines
AT mahboobimahdieh evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines
AT gholamiparizadelaheh evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines
AT behzadielham evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines
AT khosraviafra evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines